Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.5.1821

Association between the NQO1 C609T Polymorphism with Hepatocellular Carcinoma Risk in the Chinese Population  

Zhao, Hong (Department of Radiology, Institute: the Second Hospital of Anhui Medical University)
Zou, Li-Wei (Department of Radiology, Institute: the Second Hospital of Anhui Medical University)
Zheng, Sui-Sheng (Department of Radiology, Institute: the Second Hospital of Anhui Medical University)
Geng, Xiao-Ping (Department of Radiology, Institute: the Second Hospital of Anhui Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.5, 2015 , pp. 1821-1825 More about this Journal
Abstract
Background: Associations between the NQO1 C609T polymorphism and hepatocellular carcinoma (HCC) risk are a subject of debate. We therefore performed the present meta-analysis to evaluate links with HCC susceptibility. Materials and Methods: Several major databases (PubMed, EBSCO), the Chinese national knowledge infrastructure (CNKI) and the Wanfang database were searched for eligible studies. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to measure the strength of associations. Results: A total of 4 studies including 1,325 patients and 1,367 controls were identified. There was a significant association between NQO1 C609T polymorphism and HCC for all genetic models (allelic model: OR=1.45, 95%CI=1.23-1.72, p<0.01; additive model: OR=1.96, 95%CI=1.57-2.43, p<0.01; dominant model: OR=1.62, 95%CI=1.38-1.91, p<0.01; and recessive model: OR=1.53, 95%CI=1.26-1.84, p<0.01). On subgroup analysis, similarly results were identified in Asians. For Asians, the combined ORs and 95% CIs were (allelic model: OR=1.50, 95%CI=1.24-1.82, p<0.01; additive model: OR=2.11, 95%CI=1.48-3.01, p<0.01; dominant model: OR=1.69, 95%CI=1.42-2.02, p<0.01; and recessive model: OR=1.59, 95%CI=1.16-2.19, p<0.01). Conclusions: The current meta-analysis suggested that the NQO1 C609T polymorphism could be a risk factor for developing HCC, particularly in the Chinese population.
Keywords
Hepatocellular carcinoma; NQO1; polymorphism; meta-analysis; Chinese;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Akkiz H, Bayram S, Bekar A, et al (2010). No association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and risk of hepatocellular carcinoma development in Turkish subjects. Asian Pac J Cancer Prev, 11, 1051-8.
2 Bowen DG, Walker CM (2005). Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature, 436, 946-52.   DOI
3 de Lope CR, Tremosini S, Forner A, et al (2012). Management of HCC. J Hepatol, 56, 75-87.
4 Dinkova-Kostova AT, Talalay P (2010). NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys, 501, 116-23.   DOI
5 Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.   DOI
6 El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76.   DOI
7 Farazi PA, DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87.   DOI
8 Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.   DOI
9 Hu X, Zhang Z, Ma D, et al (2010). TP53, MDM2, NQO1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev, 19, 755-61.   DOI
10 Kato N, Ji G, Wang Y, et al (2005). Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology, 42, 846-53.   DOI
11 Kim YJ, Lee HS (2005). Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology, 48, 10-5.   DOI
12 Lau J, Ioannidis JP, Schmid CH (1997). Quantitative synthesis in systematic reviews. Ann Intern Med, 127, 820-6.   DOI
13 Liu F, Luo L, Wei Y, et al (2013). A functional NQO1 609C>T polymorphism and risk of hepatocellular carcinoma in a Chinese population. Tumour Biol, 34, 47-53.   DOI
14 Malik MA, Zargar SA, Mittal B (2011). Role of NQO1 609C>T and NQO2-3423G>A polymorphisms in susceptibility to gastric cancer in Kashmir valley. DNA Cell Biol, 30, 297-303.   DOI   ScienceOn
15 Mandal RK, Nissar K, Mittal RD (2012). Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from North India. Mol Biol Rep, 39, 11145-52.   DOI
16 Moher D, Liberati A, Tetzlaff J, et al (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med, 151, 264-9.   DOI
17 Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43.   DOI
18 Peng XE, Jiang YY, Shi XS, et al (2013). NQO1 609C>T polymorphism interaction with tobacco smoking and alcohol drinking increases colorectal cancer risk in a Chinese population. Gene, 521, 105-10.   DOI
19 Tan SK, Qiu XQ, Tang GF, et al (2012). Relationship between hepatocellular carcinoma and the interaction between NQO1 polymorphisms and environmental factors. Zhonghua Gan Zang Bing Za Zhi, 20, 833-7.
20 Siegel D, Yan C, Ross D (2012). NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol, 83, 1033-40.   DOI
21 Traver RD, Siegel D, Beall HD, et al (1997). Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer, 75, 69-75.   DOI
22 Wang WW, Chen GY, Sun JJ, et al (2013). The relationship between polymorphisms of NQO1 genes and hepatocellular carcinoma in Zhengzhou and Guilin areas. Chin J Hepatobiliary Surg, 19, 836-40.
23 Yuan W, Xu L, Chen W, et al (2011). Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat, 125, 467-72.   DOI
24 Yuen MF, Hou JL, Chutaputti A, et al (2009). Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol, 24, 346-53.   DOI